"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...
Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...
MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...
Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the ...
The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results